Ritonavir & Ritonavir-Boosted Protease Inhibitors/Boceprevir Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Boceprevir may speed up how quickly your liver processes your HIV medicine. Your HIV medicine may speed up how quickly your liver processes boceprevir.
What might happen:
Your medicines may not work as well in treating your HIV and your hepatitis.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together and discuss the risks and benefits of using these medicines together. Your doctor may want to run some tests to see how your medicines are working. Your doctor may want to change your medicine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Reddy SSK. Dear US Healthcare Professional: SUBJECT: Results of Pharmacokinetic Study in Healthy Volunteers Given VICTRELIS (boceprevir) and Ritonavir-Boosted HIV Protease Inhibitors May Indicate Clinically Significant Drug Interactions for. Patients Coinfected with Chronic Hepatitis C and HIV. Merck & Co., Inc. February 6, 2012.
- 2.US Food and Drug Administration. FDA Drug Safety Communication: Important drug interactions between Victrelis (boceprevir) and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitor drugs. Available at:http://wayback.archive-it.org/7993/20161022203820/http://www.fda.gov/Dr ugs/DrugSafety/ucm291119.htm February 8, 2012.
- 3.USFood and Drug Administration. FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs. available at: http://www.fda.gov/Drugs/DrugSafety/ucm301616.htm April 26, 2012.
- 4.Victrelis (boceprevir) US prescribing information. Schering Corporation January, 2017.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.